Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Third Cell Therapy For Lymphoma Approved In The US

Executive Summary

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

You may also be interested in...



Be Bio’s New $130m Raise Will Advance B-Cell Therapies Toward The Clinic

Biotech is developing engineered B-cell therapeutics for rare diseases and cancer. They should offer greater duration and better tolerability than T-cell therapies, the company claims.

Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma

Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.

BMS ‘Slow-Rolled’ Approval of Liso-Cel, Investors Claim, Citing Timeline Of Other CAR-T Therapies

Two complaints allege BMS deliberately delayed approval of non-Hodgkins lymphoma treatment to avoid $6.4bn contingency payment. Former FDA reviewer is expert for plaintiffs in securities class action arguing that similar cell therapies Yescarta and Kymriah were approved twice as fast.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel